Understanding and Treatment of Premenstrual Dysphoric Disorder / 대한정신약물학회지

ABSTRACT

Many reproductive women, at least 20-50%, suffered from premenstrual syndrome and 2-8% of them have premenstrual dysphoric disorder(PMDD). Prospective daily records during 2 menstrual cycles are required to differentiate PMDD from other various similar conditions such as concurrent psychiatric or medical diseases or their premenstrual magnification and also to determine the efficacy of treatment. The etiology of PMDD is largely unknown. Recently as several randomized placebo-controlled trial in women with PMDD have reported the efficacy of serotonin reuptake inhibitors(SSRIs), SSRIs have been preferred to other treatment regimens though response rates to SSRIs were variable with high placebo response rate and though their long-term and preventive effect were not yet determined.